2021
DOI: 10.1002/prot.26275
|View full text |Cite
|
Sign up to set email alerts
|

Prokaryotic expression, evaluation, and prediction of the structure and function of the ecarin metalloproteinase domain

Abstract: Ecarin is one of the most widely used drug compounds in blood clotting experiments and is used to monitor and treat many diseases such as cancer, liver, lupus, and cardiovascular disease. The metalloproteinase domain is known as the active site of ecarin. In this study, an ecarin metalloproteinase cassette was designed and synthesized in the pUC57 vector. The gene fragment was released and

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…According to the Jonebring et al study, the highest yield of CHO- produced ecarin was up to 7000 EU ecarin/litre in lab scale shaker cultures (equivalent to ~5500 mU/L), but the recovery percentage of the purified rEcarin was not reported [ 13 ]. Very recently, Mohammadi et al reported that the ecarin metalloproteinase domain was expressed in E. coli , with high plasma clotting activity, but it is unclear whether expression of the metalloproteinase domain could be scaled up to produce high yield [ 17 ]. In our study, we obtained a purification recovery of 76% of rEcrain and the yield of the purified rEcarin was 18.7 mg/L, with the prothrombin activity at 6100 mU/L (7820 IU/L).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…According to the Jonebring et al study, the highest yield of CHO- produced ecarin was up to 7000 EU ecarin/litre in lab scale shaker cultures (equivalent to ~5500 mU/L), but the recovery percentage of the purified rEcarin was not reported [ 13 ]. Very recently, Mohammadi et al reported that the ecarin metalloproteinase domain was expressed in E. coli , with high plasma clotting activity, but it is unclear whether expression of the metalloproteinase domain could be scaled up to produce high yield [ 17 ]. In our study, we obtained a purification recovery of 76% of rEcrain and the yield of the purified rEcarin was 18.7 mg/L, with the prothrombin activity at 6100 mU/L (7820 IU/L).…”
Section: Discussionmentioning
confidence: 99%
“…However, the use of ecarin purified from snake venoms has many of the drawbacks of OsPA and PtPA; therefore, it is desirable to have a recombinantly expressed form. The cloning and expression of ecarin in active form, including within the metalloproteinase domain, have been previously described in different systems [ 13 , 17 , 18 , 19 ]. However, it has not been demonstrated whether these recombinant forms can be scaled up to produce a commercial supply of recombinant ecarin.…”
Section: Introductionmentioning
confidence: 99%
“…The aim of this study was to produce safe, cost-effective, and high-performance r-Ecarin for diagnostic, and therapeutic purposes. Comparing the expression and function of full-length and truncated forms of this protein obtained from the previous study (19) helps to select the right one for production.…”
Section: Objectivesmentioning
confidence: 99%